An independent peptide reference — no sellers, every claim sourced

GDF-11

Also known as Growth Differentiation Factor 11, GDF11, BMP-11

TGF-beta family protein at the centre of an unresolved scientific dispute about whether it rejuvenates or harms tissue.

preclinical Immune & longevity research chemical

At a glance

Category
Immune & longevity
Status
research chemical
Made from
recombinant Recombinant protein produced in cell culture and sold as a research reagent; preparations differ in purity and in whether the mature dimer or a pro-form is supplied.
Route
intraperitoneal and subcutaneous in rodent studies; injected subcutaneously in unvalidated consumer use
Half-life
No published human pharmacokinetics. In circulation GDF-11 exists largely as a latent pro-complex rather than free mature dimer, so a simple plasma half-life figure would in any case be misleading. Any half-life quoted by a supplier has no primary source.
Molecular weight
approximately 25 kDa for the mature dimer; the precursor is considerably larger and circulates as a latent complex with its own prodomain 6
Sequence
Mature GDF-11 is a 109-residue polypeptide that forms a disulphide-linked homodimer; the mature domain shares roughly 90% amino acid identity with myostatin (GDF-8). This near-identity is the single most important fact about the compound and the direct cause of the scientific controversy around it.

Recombinant GDF-11 is a laboratory reagent, sold for research use only. It is not approved as a medicine anywhere, has never been the subject of a published human clinical trial, and is not a supplement. It is nevertheless resold to consumers as an anti-ageing injectable. Note that GDF-11 is not a peptide but a full disulphide-linked dimeric growth factor of the TGF-beta superfamily; correct folding and dimerisation are essential to activity and cannot be verified by the purchaser.

Doping status: Not listed by name; as a non-approved substance it falls under S0 and is therefore prohibited at all times. Note that myostatin-pathway modifiers are explicitly prohibited under S2, and GDF-11 signals through the same receptors.

Checked against the WADA 2026 Prohibited List. For a specific product and country, Global DRO is the lookup athletes are expected to use — the List names substances, not brand names.

Mechanism of action

GDF-11 is a member of the TGF-beta superfamily. It is secreted as a latent precursor, activated by proteolytic processing, and signals through activin type II receptors (ActRIIA and ActRIIB) and the ALK4/ALK5/ALK7 type I receptors, driving SMAD2/3 phosphorylation and downstream transcription. During embryogenesis it has a well-established and uncontroversial role in anterior-posterior axial patterning and in skeletal and neural development.

The adult role is where the dispute lies. GDF-11 and myostatin bind the same receptors and activate the same SMAD2/3 pathway. Myostatin is the canonical negative regulator of skeletal muscle mass. It is therefore biologically expected, on receptor grounds alone, that supraphysiological GDF-11 would suppress rather than promote muscle growth - and that is what several groups have observed. Germline replacement experiments have shown that GDF-11 can functionally substitute for myostatin in mice, which is difficult to reconcile with the two proteins having opposite effects on muscle 7.

The 'rejuvenation' hypothesis proposed something different: that circulating GDF-11 declines with age and that restoring it reverses age-related cardiac hypertrophy, improves skeletal muscle stem cell function and enhances neurogenesis and cerebral vasculature. If true, GDF-11 would be a systemic youth factor. The mechanism by which the same ligand on the same receptors would rejuvenate heart and muscle while its near-twin does the opposite has never been satisfactorily explained, and this gap is part of why the original findings were challenged.

A partial reconciliation that is sometimes offered is that GDF-11 has a biphasic dose-response: physiological concentrations are beneficial, supraphysiological concentrations are catabolic. This is plausible and would explain some of the discrepant results, but it is a hypothesis fitted after the fact rather than a demonstrated property, and it has an uncomfortable implication for anyone injecting the protein - the therapeutic window, if one exists, is unknown and narrow.

What the research shows

This is a genuine unresolved scientific controversy, not a case of one side being obviously right. The original heterochronic parabiosis work reported striking rejuvenation effects and appeared in Cell and Science 12. Independent groups then showed that the assays used to measure GDF-11 could not distinguish it from myostatin, that GDF-11 does not decline with age when measured by mass spectrometry, and that GDF-11 administration can impair muscle regeneration 34. Later work has partially rehabilitated some cardiac and cerebrovascular findings. What has not happened in more than a decade is convergence. There is no human trial data at all.

Research in humans

No published clinical trial of administered GDF-11 in humans exists. The only human data are observational measurements of endogenous levels, and these are exactly what is contested. Schafer and colleagues (Cell Metabolism, 2016) developed a targeted LC-MS/MS assay capable of separating GDF-11 from myostatin and reported that circulating GDF-11 does not decline with age in humans; myostatin declined in healthy men, and neither changed with age in healthy women 4. In older adults with severe aortic stenosis, higher rather than lower GDF-11 was associated with frailty, diabetes and prior cardiac disease, and higher preoperative GDF-11 predicted rehospitalisation and adverse events after valve replacement 4. That is the opposite direction from the youth-factor hypothesis. Other cohorts using different assays have reported different associations, and some more recent work distinguishing activated GDF-11/8 subforms reports associations with cardiovascular events. The honest summary is that we do not reliably know what circulating GDF-11 does in humans, in part because we only recently acquired assays capable of measuring it specifically.

Animal and lab research

Loffredo and colleagues (Cell, 2013) reported that GDF-11 was a circulating factor that reversed age-related cardiac hypertrophy in mice, identified through heterochronic parabiosis 1. Sinha and colleagues (Science, 2014) reported that restoring systemic GDF-11 improved skeletal muscle stem cell function and muscle regeneration in aged mice 2. Katsimpardi and colleagues reported improvements in neurogenesis and cerebral vasculature. Against this, Egerman and colleagues (Cell Metabolism, 2015), working at Novartis, reported that GDF-11 levels increase rather than decrease with age in rats and humans and that GDF-11 administration inhibited skeletal muscle regeneration in mice - directly contradicting the Sinha result 3. Critically, Egerman's group demonstrated that the aptamer-based and antibody-based assays used in the earlier work cross-reacted with myostatin, meaning the original measurements of 'declining GDF-11' may have been measuring something else 3. Subsequent studies have variously supported the cardiac findings, failed to replicate the muscle findings, and reported cachexia and weight loss at higher GDF-11 doses.

Caveats. The core methodological problem is assay specificity: 90% sequence identity in the mature domain defeats most antibodies and aptamers, so a substantial part of the pre-2016 literature measured a GDF-11/myostatin composite of unknown proportions 3. Findings therefore cannot be pooled across studies using different assays, and older papers cannot simply be re-interpreted. Beyond that: recombinant GDF-11 preparations differ in purity, activity and whether the mature dimer or a pro-form is supplied, and biological potency has varied between commercial lots 6; dose is inconsistent across studies and the biphasic hypothesis means dose differences alone could produce opposite results; parabiosis experiments transfer thousands of factors, so attributing an effect to one of them requires the specificity that the assays did not provide; and several of the key studies come from research groups with commercial interests in the outcome on both sides of the dispute. There is no human trial, no toxicology programme, and no established safe dose.

What it is used for

  • Laboratory reagent in ageing, cardiac and muscle biology research
  • Sold on the grey market as an anti-ageing and 'systemic rejuvenation' injectable, with no human data supporting any indication
  • Occasionally promoted for muscle or cardiac benefit - a use in direct tension with the evidence that GDF-11 administration inhibited skeletal muscle regeneration in mice and that circulating levels rise rather than fall with age 34

Dosing

  • There is no human dose, because there has never been a human trial. Rodent studies typically used approximately 0.1 mg/kg per day intraperitoneally, but the disputed literature means that even the rodent dose-effect relationship is not agreed upon.
  • If the biphasic hypothesis is correct, the difference between a beneficial and a harmful dose may be small and is entirely unmapped in humans. That is a reason not to guess, not a reason to pick a middle figure.
  • Any dosing protocol circulating online is invented. There is no source it could honestly cite.
  • Recombinant GDF-11 sold as a research reagent is priced and packaged for cell culture, and its specific activity is lot-dependent; two vials of nominally identical material may not be biologically equivalent.

These figures describe what the literature and published protocols report. They are not advice and not a dosing instruction.

Reconstitution

Storage
Research-grade recombinant GDF-11 is supplied lyophilised, usually with a carrier protein, and is stored at -20 °C or below with aliquoting to avoid freeze-thaw cycles. These are reagent handling instructions for laboratory use.

No injection-preparation guidance is given here. GDF-11 is a disulphide-linked dimeric growth factor whose activity depends on correct folding; a purchaser cannot verify that the material in a vial is correctly folded, correctly dimerised, or GDF-11 rather than myostatin - and given the 90% identity, even a supplier's analytical certificate would struggle to distinguish them.

Safety

Side effects

  • Unknown in humans - no person has been dosed in a published study
  • In rodents, higher-dose GDF-11 has been associated with weight loss, cachexia-like wasting and impaired skeletal muscle regeneration 3
  • Effects on erythropoiesis are plausible: activin receptor ligands in this family suppress late-stage erythroid maturation, which is the basis for drugs such as luspatercept that block the pathway; adding ligand would be expected to push in the opposite direction
  • Bone and cartilage effects are possible given the developmental roles of the pathway, and have not been characterised in adults
  • Immunogenicity against a recombinant human protein of unverified purity is a real and unassessed risk

Do not use if

  • Anyone with sarcopenia, muscle wasting, cachexia or a catabolic illness - the evidence that GDF-11 administration impairs skeletal muscle regeneration in mice makes this the worst-case population 3
  • Existing anaemia or any condition affecting erythropoiesis
  • Active or past malignancy - TGF-beta superfamily signalling has context-dependent and sometimes tumour-promoting effects, entirely unstudied here
  • Pregnancy and breastfeeding - GDF-11 has defined roles in embryonic axial patterning; this is a specific and serious concern, not a boilerplate caution
  • Children and adolescents - the pathway is developmentally active
  • Concurrent treatment with activin-pathway drugs such as luspatercept or sotatercept

Interactions

Not studied. Pharmacologically, GDF-11 would be expected to oppose drugs that block the activin/myostatin pathway (luspatercept, sotatercept, myostatin-directed antibodies) and to interact unpredictably with follistatin or follistatin-derived products, which are natural antagonists of this ligand family. None of this has been tested.

Sources